Floatz logo

MERCAPTOPURINE ANHYDROUS

Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

National Cancer Institute (NCI)Small moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

52 Active assets in the Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

MERCAPTOPURINE ANHYDROUS is also rated in:

adult acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
80 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →